Kevin Little is a Senior Partnership Director with Novo Nordisk, overseeing the development and management of the company’s portfolio of strategic research collaborations in the US.
Kevin has held various executive roles in the life sciences, most recently as Chief Scientific Officer of 3D Signatures Inc. He previously led the start-up of Concordia University’s PERFORM Centre in preventive health, after several years leading the New Zealand government’s economic development efforts to build strategic investment relationships across the biotechnology industry sector.
Kevin holds a Bachelor of Science degree in Biology from the University of Victoria, and a Ph.D. in Experimental Medicine from McGill University. He completed a postdoctoral fellowship in translational neuroscience and clinical gene therapy at the University of Auckland in New Zealand, and is a Certified Strategic Alliance Professional.